the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Korábbi kezelés

• Diagnosed as other malignant diseases other than NSCLC within 5 years prior to initial administration (excluding curative basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curative resection of carcinoma in situ);
• Stroke or cardiovascular events within 6 months prior to enrollment
• Previously received hematopoietic stem cell or bone marrow transplantation
• Allergy to the investigational drug or its components;

Más betegség

• Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA grade III or IV);

Egyéb

• When screening, QTcF interval>480msec, for patients with implanted ventricular pacemakers, QTcF>500msec
• The researchers believe that it is not suitable to participate in this study.

• Age ≥ 18 years old, regardless of gender;
• Patients with locally advanced and late stage (IIIB, IIIC, IV) NSCLC who have been confirmed by histopathology and cannot be surgically removed (without local symptoms (with or without brain metastasis)) have at least one measurable lesion that meets the RECIST 1.1 criteria
• Need to receive chemotherapy treatment (first-line chemotherapy treatment uses platinum+pemetrexed/docetaxel/albumin paclitaxel/paclitaxel; second-line chemotherapy treatment: choose the above first-line chemotherapy treatment without using chemotherapy drugs; (Note: If first-line chemotherapy treatment does not combine with immunotherapy, subsequent increase in immunotherapy patients will not be counted as an increase in the number of treatment lines, and the number of treatment lines in this trial is limited to the number of chemotherapy treatment lines)
• The laboratory inspection meets the standards
• ECOG PS score 0-1 points;
• Women: All women with potential fertility must have a negative serum pregnancy test result during the screening period, and reliable contraceptive measures must be taken 3 months after signing the informed consent form and the last dose;
• Understand and sign the informed consent form.